Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV
Background: The aim of the study is to evaluate the effectiveness, safety, and tolerability of a two-drug regimen (2-DR) dolutegravir/lamivudine (DTG/3TC) versus a three-drug regimen (3-DR) tenofovir alafenamide/emtricitabine/bictegravir (TAF/FTC/BIC) in a real-life cohort of HIV-1 virologically sup...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/24/7759 |
| _version_ | 1797380528734732288 |
|---|---|
| author | Giuseppe Vittorio De Socio Sara Tordi Debora Altobelli Anna Gidari Anastasia Zoffoli Daniela Francisci |
| author_facet | Giuseppe Vittorio De Socio Sara Tordi Debora Altobelli Anna Gidari Anastasia Zoffoli Daniela Francisci |
| author_sort | Giuseppe Vittorio De Socio |
| collection | DOAJ |
| description | Background: The aim of the study is to evaluate the effectiveness, safety, and tolerability of a two-drug regimen (2-DR) dolutegravir/lamivudine (DTG/3TC) versus a three-drug regimen (3-DR) tenofovir alafenamide/emtricitabine/bictegravir (TAF/FTC/BIC) in a real-life cohort of HIV-1 virologically suppressed treatment-experienced (TE) people living with HIV (PLWH). Methods: This was a single-center, retrospective, observational study analyzing adult TE PLWH who started the 2-DR or 3-DR between January 2018 and January 2023. All PLWH with a viral load (VL) <50 copies/mL at the time of switching, and a follow-up of more than 6 months or interruption of treatment at any time, were included. Results: A total of 324 PLWH were included; of these, 110 (34%) were on the 2-DR and 214 (66%) were on the 3-DR. Most patients remained on therapy in both groups (93.6% 2-DR versus 90.2% 3-DR) and, at the last control, 99.1% achieved VL < 50 copies/mL with the 2-DR versus 97.2% with the 3-DR (<i>p</i> = 0.260). No virological failures occurred in either group. Adverse events occurred in a few cases: four (3.6%) in the 2-DR group and five (2.3%) in the 3-DR group (<i>p</i> = 0.500). The median follow-up-time was 19.6 months for the 2-DR and 27.5 months for the 3-DR. Conclusion: Our study shows a similar effectiveness and safety profile in virologically suppressed PLWH switching to DTG/3TC or TAF/FTC/BIC. |
| first_indexed | 2024-03-08T20:38:35Z |
| format | Article |
| id | doaj.art-22bd0869c57d4332aea28dc40cf627cf |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-08T20:38:35Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-22bd0869c57d4332aea28dc40cf627cf2023-12-22T14:17:42ZengMDPI AGJournal of Clinical Medicine2077-03832023-12-011224775910.3390/jcm12247759Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIVGiuseppe Vittorio De Socio0Sara Tordi1Debora Altobelli2Anna Gidari3Anastasia Zoffoli4Daniela Francisci5Department of Medicine, Clinic of Infectious Diseases, “Santa Maria della Misericordia” Hospital, University of Perugia, 06129 Perugia, ItalyDepartment of Medicine, Clinic of Infectious Diseases, “Santa Maria della Misericordia” Hospital, University of Perugia, 06129 Perugia, ItalyDepartment of Medicine, Clinic of Infectious Diseases, “Santa Maria della Misericordia” Hospital, University of Perugia, 06129 Perugia, ItalyDepartment of Medicine, Clinic of Infectious Diseases, “Santa Maria della Misericordia” Hospital, University of Perugia, 06129 Perugia, ItalyDepartment of Medicine, Clinic of Infectious Diseases, “Santa Maria della Misericordia” Hospital, University of Perugia, 06129 Perugia, ItalyDepartment of Medicine, Clinic of Infectious Diseases, “Santa Maria della Misericordia” Hospital, University of Perugia, 06129 Perugia, ItalyBackground: The aim of the study is to evaluate the effectiveness, safety, and tolerability of a two-drug regimen (2-DR) dolutegravir/lamivudine (DTG/3TC) versus a three-drug regimen (3-DR) tenofovir alafenamide/emtricitabine/bictegravir (TAF/FTC/BIC) in a real-life cohort of HIV-1 virologically suppressed treatment-experienced (TE) people living with HIV (PLWH). Methods: This was a single-center, retrospective, observational study analyzing adult TE PLWH who started the 2-DR or 3-DR between January 2018 and January 2023. All PLWH with a viral load (VL) <50 copies/mL at the time of switching, and a follow-up of more than 6 months or interruption of treatment at any time, were included. Results: A total of 324 PLWH were included; of these, 110 (34%) were on the 2-DR and 214 (66%) were on the 3-DR. Most patients remained on therapy in both groups (93.6% 2-DR versus 90.2% 3-DR) and, at the last control, 99.1% achieved VL < 50 copies/mL with the 2-DR versus 97.2% with the 3-DR (<i>p</i> = 0.260). No virological failures occurred in either group. Adverse events occurred in a few cases: four (3.6%) in the 2-DR group and five (2.3%) in the 3-DR group (<i>p</i> = 0.500). The median follow-up-time was 19.6 months for the 2-DR and 27.5 months for the 3-DR. Conclusion: Our study shows a similar effectiveness and safety profile in virologically suppressed PLWH switching to DTG/3TC or TAF/FTC/BIC.https://www.mdpi.com/2077-0383/12/24/7759HIVdolutegravirbictegravirvirological failuresafetytoxicity |
| spellingShingle | Giuseppe Vittorio De Socio Sara Tordi Debora Altobelli Anna Gidari Anastasia Zoffoli Daniela Francisci Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV Journal of Clinical Medicine HIV dolutegravir bictegravir virological failure safety toxicity |
| title | Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV |
| title_full | Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV |
| title_fullStr | Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV |
| title_full_unstemmed | Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV |
| title_short | Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV |
| title_sort | dolutegravir lamivudine versus tenofovir alafenamide emtricitabine bictegravir as a switch strategy in a real life cohort of virogically suppressed people living with hiv |
| topic | HIV dolutegravir bictegravir virological failure safety toxicity |
| url | https://www.mdpi.com/2077-0383/12/24/7759 |
| work_keys_str_mv | AT giuseppevittoriodesocio dolutegravirlamivudineversustenofoviralafenamideemtricitabinebictegravirasaswitchstrategyinareallifecohortofvirogicallysuppressedpeoplelivingwithhiv AT saratordi dolutegravirlamivudineversustenofoviralafenamideemtricitabinebictegravirasaswitchstrategyinareallifecohortofvirogicallysuppressedpeoplelivingwithhiv AT deboraaltobelli dolutegravirlamivudineversustenofoviralafenamideemtricitabinebictegravirasaswitchstrategyinareallifecohortofvirogicallysuppressedpeoplelivingwithhiv AT annagidari dolutegravirlamivudineversustenofoviralafenamideemtricitabinebictegravirasaswitchstrategyinareallifecohortofvirogicallysuppressedpeoplelivingwithhiv AT anastasiazoffoli dolutegravirlamivudineversustenofoviralafenamideemtricitabinebictegravirasaswitchstrategyinareallifecohortofvirogicallysuppressedpeoplelivingwithhiv AT danielafrancisci dolutegravirlamivudineversustenofoviralafenamideemtricitabinebictegravirasaswitchstrategyinareallifecohortofvirogicallysuppressedpeoplelivingwithhiv |